| Medical and Health Sciences | Lifetime | 586 | NL 17 | 99.97 |
| Medical and Health Sciences | 2021-2025 | 230 | NL 3 | 99.96 |
| Medical Genetics | Lifetime | 8 | NL 1 | 99.92 |
| Pulmonary and Respiratory Medicine | Lifetime | 347 | NL 8 | 99.57 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 789 | NL 17 | 97.89 |
| Clinical Neurology | Lifetime | 517 | NL 18 | 97.70 |
| Cancer Research | Lifetime | 721 | NL 14 | 94.99 |
| Medical Genetics | 2021-2025 | 3 | NL 1 | 99.91 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 217 | NL 4 | 98.34 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 180 | NL 7 | 96.54 |
| Pediatrics, Perinatology and Child Health | 2021-2025 | 440 | NL 14 | 89.51 |
| Clinical Neurology | 2021-2025 | 362 | NL 13 | 88.67 |
| Radiomics and Machine Learning in Medical Imaging | Lifetime | 8 | NL 3 | 99.89 |
| Glioma Diagnosis and Treatment | Lifetime | 7 | NL 1 | 99.95 |
| Brain Metastases and Treatment | Lifetime | 4 | NL 1 | 99.94 |
| Meningioma and schwannoma management | Lifetime | 14 | NL 1 | 99.85 |
| Neuroblastoma Research and Treatments | Lifetime | 25 | NL 2 | 99.66 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 89 | NL 1 | 99.64 |
| Histone Deacetylase Inhibitors Research | Lifetime | 34 | NL 1 | 99.51 |
| Cancer Treatment and Pharmacology | Lifetime | 242 | NL 7 | 99.23 |
| Cancer Genomics and Diagnostics | Lifetime | 647 | NL 21 | 98.82 |
| Management of metastatic bone disease | Lifetime | 128 | NL 4 | 98.09 |
| Ocular Oncology and Treatments | Lifetime | 100 | NL 4 | 97.79 |
| CNS Lymphoma Diagnosis and Treatment | Lifetime | 99 | NL 2 | 98.61 |
| Chromatin Remodeling and Cancer | Lifetime | 77 | NL 3 | 97.64 |
| Cancer-related cognitive impairment studies | Lifetime | 96 | NL 8 | 97.46 |
| Lung Cancer Research Studies | Lifetime | 709 | NL 30 | 97.65 |
| MRI in cancer diagnosis | Lifetime | 573 | NL 35 | 97.21 |
| Chemotherapy-related skin toxicity | Lifetime | 706 | NL 28 | 83.15 |
| Glioma Diagnosis and Treatment | 2021-2025 | 3 | NL 1 | 99.94 |
| Brain Metastases and Treatment | 2021-2025 | 3 | NL 1 | 99.87 |
| Neuroblastoma Research and Treatments | 2021-2025 | 3 | NL 1 | 99.32 |
| Meningioma and schwannoma management | 2021-2025 | 6 | NL 1 | 99.51 |
| Radiomics and Machine Learning in Medical Imaging | 2021-2025 | 40 | NL 4 | 99.30 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 262 | NL 2 | 93.86 |
| Medical Imaging Techniques and Applications | 2021-2025 | 519 | NL 35 | 94.19 |
| Cancer-related cognitive impairment studies | 2021-2025 | 82 | NL 6 | 92.63 |
| MRI in cancer diagnosis | 2021-2025 | 813 | NL 35 | 84.65 |
| Epilepsy research and treatment | 2021-2025 | 922 | NL 15 | 86.96 |
| Pharmacological Effects and Toxicity Studies | 2021-2025 | 583 | NL 18 | 83.96 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 616 | NL 9 | 80.42 |
| Management of metastatic bone disease | 2021-2025 | 475 | NL 19 | 81.30 |
| CNS Lymphoma Diagnosis and Treatment | 2021-2025 | 593 | NL 21 | 76.19 |
| Drug Transport and Resistance Mechanisms | 2021-2025 | 942 | NL 31 | 73.27 |
| Chromatin Remodeling and Cancer | 2021-2025 | 390 | NL 8 | 70.74 |
| Ocular Oncology and Treatments | 2021-2025 | 629 | NL 40 | 71.08 |
